HK Stock Market Move | LIVZON PHARMA (01513) continues to fall over 3%, with net profit attributable to the parent company in the second quarter down 40% year-on-year, showing a significant decline in the chemical preparations and traditional Chinese medicine segments.

After a nearly 16% drop yesterday, LIVZON PHARMA (01513) continued to decline by over 3%, touching a new low of HK$20.18 during the trading session, the lowest in over two years. As of this writing, it has fallen 3.33% to HK$20.3, with a trading volume of HK$72.049 million. In terms of news, LIVZON PHARMA recently released its mid-year results for 2026, reporting an operating income of approximately RMB 5 billion for the first half of the year, a year-on-year decrease of 20.28%; the net profit attributable to the parent companys shareholders was RMB 932 million, a year-on-year decrease of 27.23%. Specifically for the second quarter, the company achieved an operating income of RMB 2.13 billion, a year-on-year decline of 31.1%; the net profit attributable to the parent company was RMB 355 million, down 44.9% year-on-year. Examining specific business areas, the significant decline in the performance of chemical formulations and traditional Chinese medicine formulations has become the main factor dragging down the companys overall revenue. During the reporting period, the sales revenue of the chemical formulations business sector fell by 25.33%, primarily affected by price reductions in medical insurance and national centralized procurement; the sales revenue of traditional Chinese medicine formulations and other business sectors declined by 34.83%. This is attributed to a decrease in the prevalence of influenza and respiratory diseases in the domestic market during the first quarter of this year, leading to a drop in demand for related products.